Elanco Animal Health (NYSE:ELAN) Releases Q4 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.160-0.190 for the period, compared to the consensus EPS estimate of 0.180. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.170-1.200 EPS.

Wall Street Analyst Weigh In

Several brokerages recently commented on ELAN. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a report on Friday, October 16th. They set a “buy” rating and a $32.00 price target on the stock. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Morgan Stanley dropped their target price on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, October 29th. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Finally, UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Elanco Animal Health Trading Up 8.3%

NYSE ELAN opened at $25.65 on Friday. The company’s 50-day moving average price is $23.13 and its 200-day moving average price is $23.82. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The stock has a market cap of $12.81 billion, a PE ratio of -85.48, a PEG ratio of 2.28 and a beta of 1.73. Elanco Animal Health has a 12 month low of $19.40 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the previous year, the company earned $0.19 EPS. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Kurzius acquired 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was bought at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the purchase, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Harrington bought 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the acquisition, the director owned 131,451 shares in the company, valued at $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 48,998 shares of company stock worth $1,139,373. Corporate insiders own 1.14% of the company’s stock.

Key Headlines Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

About Elanco Animal Health

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.